Canadian Approval of Revolutionary ZORYVE™ Cream: A Breakthrough in the Treatment of Plaque Psoriasis

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is pleased to announce that its next-generation topical PDE4 inhibitor therapy for plaque psoriasis, ZORYVE™ (roflumilast) cream 0.3%, has officially been approved by Health Canada. This groundbreaking innovation in immuno-dermatology provides a promising new treatment option for those living with plaque psoriasis.

ZORYVE is a revolutionary topical treatment for plaque psoriasis, now available in Canada for individuals aged 12 and above. It is ideal for treating psoriasis in intertriginous areas, and its efficacy has been confirmed in the full Canadian product monograph. Don’t let psoriasis hold you back: try ZORYVE today and get back to living your best life!

Arcutis is delighted to announce the successful approval of ZORYVE in Canada. This steroid-free cream provides a safe and effective topical treatment for plaque psoriasis, demonstrating Arcutis’ ongoing commitment to providing therapies that address the most persistent challenges of immune-mediated skin diseases.

The partnership with Canadian dermatologists was crucial to the development of ZORYVE, with one-third of all clinical trials participants coming from Canada. We look forward to continuing to advance our robust pipeline in both countries.

Plaque psoriasis affects the majority of individuals and until now, topical agents have been the mainstay for treatment. ZORYVE has changed this, offering rapid clearance of plaques anywhere on the body, even in harder to treat areas such as the elbows and knees, or sensitive intertriginous areas like under the breasts, in the groin, or under the arms.

As noted by Dr. Melinda Gooderham, Assistant Professor at Queen’s University, Medical Director at the SKiN Centre for Dermatology and Principal Investigator for the SKiN Research Centre in Peterborough, Ontario, ZORYVE is a groundbreaking treatment for psoriasis.

Today marks a momentous milestone for Arcutis Biotherapeutics as their pioneering efforts to deliver innovative treatments for immune-mediated dermatological diseases and conditions are being rewarded with the first regulatory approval of ZORYVE outside of the United States. This approval stands as a testament to the company’s ongoing commitment to advancing treatments and therapies for those suffering from these conditions.


ZORYVE (roflumilast) cream 0.3% is a revolutionary topical inhibitor of phosphodiesterase-4 (PDE4) that has been approved by the FDA and Health Canada for adults and adolescents with plaque psoriasis, including intertriginous psoriasis. It is the first ever PDE4 inhibitor to be made available topically, providing a groundbreaking new treatment option for those suffering from psoriasis.

Leave a Comment